{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3227, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 14, "slideType": "traction", "function": "show_traction", "notes": "The slide details the dosing regimens for different cohorts over induction and consolidation phases.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/14", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-14", "loopMatches": [ { "to": 14, "from": 13, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "fc9a0212-bc8d-4451-b279-fd7ab70de9a7", "evidence": "Slides 13-14 present the problem and its consequences", "position": 0, "objective": "What are the consequences of not treating invasive fungal infections effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "7f5902f2-01bd-4712-8ad0-4cf1f9223757", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 14-19 present results from the EnACT study", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 15, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a process-flow diagram to present five key clinical findings.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/15", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "7f5902f2-01bd-4712-8ad0-4cf1f9223757", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 14-19 present results from the EnACT study", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 16, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The chart uses a vertical dotted line at 0.2 to denote a clinical efficacy threshold.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/16", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "7f5902f2-01bd-4712-8ad0-4cf1f9223757", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 14-19 present results from the EnACT study", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 17, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes n/N counts and specific clinical trial footnotes regarding patient outcomes and data status.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/17", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "7f5902f2-01bd-4712-8ad0-4cf1f9223757", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 14-19 present results from the EnACT study", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 18, "slideType": "traction", "function": "show_traction", "notes": "Each patient is represented by a timeline showing rapid decline in fungal load from screening to final visit day.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/18", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "7f5902f2-01bd-4712-8ad0-4cf1f9223757", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 14-19 present results from the EnACT study", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 19, "slideType": "traction", "function": "show_traction", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/19", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 19, "from": 14, "beatId": "7f5902f2-01bd-4712-8ad0-4cf1f9223757", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 14-19 present results from the EnACT study", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 20, "slideType": "roadmap", "function": "plan_implementation", "notes": "Clinical trial design diagram showing randomization into three arms with specific drug regimens over a 10-week period.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/20", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-20", "loopMatches": [ { "to": 21, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4dd339dc-619c-4f93-88e3-a04049ef8ad7", "evidence": "Slides 20-21 present the value proposition for MAT2203", "position": 1, "objective": "What is the potential for MAT2203 in the market?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 21, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a chevron-based timeline to illustrate the lifecycle management strategy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/21", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-21", "loopMatches": [ { "to": 21, "from": 20, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "4dd339dc-619c-4f93-88e3-a04049ef8ad7", "evidence": "Slides 20-21 present the value proposition for MAT2203", "position": 1, "objective": "What is the potential for MAT2203 in the market?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 22, "slideType": "solution", "function": "present_solution", "notes": "Includes MIC comparison, tissue fungal burden (lung/brain), and survival curves.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/22", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 23, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a map of the US to anchor the revenue projection and a list of four comparable deals to establish market precedent.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/23", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 23, "from": 23, "beatId": "9ce015ba-65f3-4cfd-a4c9-65b2cf21aa9f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Sizing", "beatSlug": null, "evidence": "Slide 23 presents market sizing information for MAT2203", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 24, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/24", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-24", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 25, "slideType": "traction", "function": "show_traction", "notes": "The slide highlights clinical safety and pharmacokinetic success for an oral formulation of amikacin.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/25", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 26, "slideType": "traction", "function": "show_traction", "notes": "Data presented as three distinct charts: line graph for weight, dot plot for congestion, and dot plot for viral titers.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/26", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 27, "slideType": "traction", "function": "show_traction", "notes": "The slide highlights a $2.75M upfront payment and the strategic synergy between Matinas' LNC platform and BioNTech's mRNA expertise.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/27", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 28, "slideType": "unfair_advantage", "function": "present_solution", "notes": "The slide emphasizes long-term exclusivity through both patent filings and regulatory status (QIDP/ODD).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/28", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 29, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/29", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-29", "loopMatches": [], "arcBeatMatches": [ { "to": 29, "from": 29, "beatId": "da9c46c4-69e1-4952-b1b5-905fa9eeb148", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "Slide 29 presents the leadership team", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 30, "slideType": "roadmap", "function": "plan_implementation", "notes": "Uses checkmarks for completed items and circular arrows for upcoming/potential items.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/30", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cc15-73cb-b985-dc28972c4284", "docSlug": "df7f4367d54f16f4cdacd02ff486e30b", "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 31 slides", "authorId": "matinas-biopharma", "authorName": "Matinas BioPharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7794254, "pageNumber": 31, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cc15-73cb-b985-dc28972c4284/31", "deckHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284", "deckAnchorHref": "/decks/019de073-cc15-73cb-b985-dc28972c4284#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-ccb1-712b-bbc7-d265c0614087", "docSlug": "4d1f4b45ef38db3b456fa3482c37eda5", "documentTitle": "Matson | Results Presentation Deck | 10 slides", "authorId": "matson", "authorName": "Matson", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/idqTQiBwnw5Xe_ZuN7KflhG8kX6FIpxY5hKY5118fe0/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80ZDFmNGI0NWVmMzhkYjNiNDU2ZmEzNDgyYzM3ZWRhNS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ccb1-712b-bbc7-d265c0614087/1", "deckHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087", "deckAnchorHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/TdwEGtghCfI5Tg94vM_Ex7eOGs17UGXyrCDpz6EsjhI/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80ZDFmNGI0NWVmMzhkYjNiNDU2ZmEzNDgyYzM3ZWRhNS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/OcDuNCe-RcgyZdNCc6kHI1ltxkMNttDXSi3XVQxbDIE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80ZDFmNGI0NWVmMzhkYjNiNDU2ZmEzNDgyYzM3ZWRhNS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/uSrOOcOA6ZGMcgnx7Agxe-Xl3H5UKls2dcjFO5jRvLA/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80ZDFmNGI0NWVmMzhkYjNiNDU2ZmEzNDgyYzM3ZWRhNS9wMDAxLnBuZw" }, { "docId": "019de073-ccb1-712b-bbc7-d265c0614087", "docSlug": "4d1f4b45ef38db3b456fa3482c37eda5", "documentTitle": "Matson | Results Presentation Deck | 10 slides", "authorId": "matson", "authorName": "Matson", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ccb1-712b-bbc7-d265c0614087/2", "deckHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087", "deckAnchorHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-ccb1-712b-bbc7-d265c0614087", "docSlug": "4d1f4b45ef38db3b456fa3482c37eda5", "documentTitle": "Matson | Results Presentation Deck | 10 slides", "authorId": "matson", "authorName": "Matson", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ccb1-712b-bbc7-d265c0614087/3", "deckHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087", "deckAnchorHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-ccb1-712b-bbc7-d265c0614087", "docSlug": "4d1f4b45ef38db3b456fa3482c37eda5", "documentTitle": "Matson | Results Presentation Deck | 10 slides", "authorId": "matson", "authorName": "Matson", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 4, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide presents preliminary financial data for the third quarter of 2022, including income statement components and key balance sheet items.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ccb1-712b-bbc7-d265c0614087/4", "deckHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087", "deckAnchorHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-ccb1-712b-bbc7-d265c0614087", "docSlug": "4d1f4b45ef38db3b456fa3482c37eda5", "documentTitle": "Matson | Results Presentation Deck | 10 slides", "authorId": "matson", "authorName": "Matson", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 5, "slideType": "key_messages", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ccb1-712b-bbc7-d265c0614087/5", "deckHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087", "deckAnchorHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-ccb1-712b-bbc7-d265c0614087", "docSlug": "4d1f4b45ef38db3b456fa3482c37eda5", "documentTitle": "Matson | Results Presentation Deck | 10 slides", "authorId": "matson", "authorName": "Matson", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 6, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart compares quarterly container volumes between 2021 and 2022.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ccb1-712b-bbc7-d265c0614087/6", "deckHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087", "deckAnchorHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-ccb1-712b-bbc7-d265c0614087", "docSlug": "4d1f4b45ef38db3b456fa3482c37eda5", "documentTitle": "Matson | Results Presentation Deck | 10 slides", "authorId": "matson", "authorName": "Matson", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 7, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart shows a 15.1% decrease in Q3 2022 volume compared to Q3 2021.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ccb1-712b-bbc7-d265c0614087/7", "deckHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087", "deckAnchorHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087#slide-7", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-ccb1-712b-bbc7-d265c0614087", "docSlug": "4d1f4b45ef38db3b456fa3482c37eda5", "documentTitle": "Matson | Results Presentation Deck | 10 slides", "authorId": "matson", "authorName": "Matson", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 8, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart compares quarterly container volumes between 2021 and 2022.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ccb1-712b-bbc7-d265c0614087/8", "deckHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087", "deckAnchorHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087#slide-8", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-ccb1-712b-bbc7-d265c0614087", "docSlug": "4d1f4b45ef38db3b456fa3482c37eda5", "documentTitle": "Matson | Results Presentation Deck | 10 slides", "authorId": "matson", "authorName": "Matson", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 9, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Includes a footnote regarding 4Q21 volume benefit from a 53rd week.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ccb1-712b-bbc7-d265c0614087/9", "deckHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087", "deckAnchorHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087#slide-9", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-ccb1-712b-bbc7-d265c0614087", "docSlug": "4d1f4b45ef38db3b456fa3482c37eda5", "documentTitle": "Matson | Results Presentation Deck | 10 slides", "authorId": "matson", "authorName": "Matson", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 10, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart shows quarterly operating income for 2021 and 2022, with Q3 2022 highlighted as a range.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ccb1-712b-bbc7-d265c0614087/10", "deckHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087", "deckAnchorHref": "/decks/019de073-ccb1-712b-bbc7-d265c0614087#slide-10", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/t98jmTSD4biOcGmld0Xcaq2lqP1ctyP0Ri7N7DVOcJY/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zMDNjNDUwODJiYjY5MmFiMjE0ZjczZWRhNDMxNjhkYy9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/1", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/YDIChuX-OIC5JLcH2CMbMDbuURn9VVHD9V61uRXpN6g/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zMDNjNDUwODJiYjY5MmFiMjE0ZjczZWRhNDMxNjhkYy9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/QDfJbw_0WZ8svA2zAo3J2p6gYqqf66_OZ4Y5vP8IQ2Y/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zMDNjNDUwODJiYjY5MmFiMjE0ZjczZWRhNDMxNjhkYy9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/BR7O3VZnqUvgWHBI8o8B90cil7QEN_-3PhqP5Jr77jk/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zMDNjNDUwODJiYjY5MmFiMjE0ZjczZWRhNDMxNjhkYy9wMDAxLnBuZw" }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/2", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "disclaimer", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/3", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "executive_summary", "function": "establish_context", "notes": "The slide details a strategic partnership involving equity investment and asset licensing.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/4", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "appendix_disclosure", "function": "summarize", "notes": "Includes details on upfront payments, private placement, and milestone/royalty structures.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/5", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a Gantt-style visualization to map drug development stages against specific clinical indications and future catalysts.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/6", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "timeline", "function": "plan_implementation", "notes": "NASH (Non-Alcoholic Steatohepatitis); IND (Investigational New Drug); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/7", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-7", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "thesis_headline", "function": "establish_context", "notes": "The slide serves as a title or introductory page for a specific drug candidate.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/8", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-8", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "key_takeaways", "function": "summarize", "notes": "Includes definitions of acronyms and citations for preclinical studies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/9", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-9", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "appendix_data", "function": "analyze_data", "notes": "Study methodology involves 10-week treatment on high fat/fructose/CHO diet.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/10", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-10", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "appendix_data", "function": "analyze_data", "notes": "Study design timeline included; statistical significance noted for treatment groups.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/11", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-11", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Includes definitions for abbreviations and source citations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/12", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-12", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "other", "function": "establish_context", "notes": "NASH (Non-Alcoholic Steatohepatitis); NAFLD (Non-Alcoholic Fatty Liver Disease); T2DM (Type 2 Diabetes Mellitus); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/13", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-13", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "cover", "function": "establish_context", "notes": "Company branding slide for a specific drug candidate.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/14", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-14", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "other", "function": "establish_context", "notes": "The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/15", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-15", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "appendix_data", "function": "analyze_data", "notes": "Data from preclinical study in HF-DIO mice.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/16", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-16", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "comparison_table", "function": "analyze_data", "notes": "The slide highlights that DA-1726 efficacy is likely due to dual GLP1R/GCGR agonism.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/17", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-17", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "comparison_table", "function": "analyze_data", "notes": "Study uses male DIO-NASH mice with 30-week GAND feeding and 9-week treatment regimen.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/18", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-18", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes study methodology timeline and statistical significance markers.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/19", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-19", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "appendix_data", "function": "summarize", "notes": "NASH (Non-Alcoholic Steatohepatitis); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose); PK (Pharmacokinetic); PD (Pharmacodynamic); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/20", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-20", "loopMatches": [ { "to": 20, "from": 8, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential", "position": 1, "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 20, "from": 8, "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents DA-1241 and DA-1726 as potential solutions", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 20, "from": 9, "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/21", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-21", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "market_sizing", "function": "size_opportunity", "notes": "Includes a bar chart for NASH diagnosis and a funnel diagram for Obesity patient progression.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/22", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-22", "loopMatches": [ { "to": 22, "from": 22, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7510a2ac-079c-414c-b25b-14aaafef2619", "evidence": "The document highlights the significant unmet need in NASH and T2DM", "position": 0, "objective": "What is the cost of not addressing NASH and T2DM?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 22, "from": 22, "beatId": "0b489985-a547-4b6b-9a50-ab19a3e93367", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document identifies a significant unmet need in NASH and T2DM", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 22, "from": 22, "beatId": "3108622d-a3c1-4546-b637-5070d586c3e8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "The document provides an overview of the market opportunity", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "comparison_table", "function": "compare_peers", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/23", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-23", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "competitive_analysis", "function": "quantify_opportunity", "notes": "The slide highlights rapid adoption compared to Saxenda and notes supply chain issues impacting Q4'21 and H1'22.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/24", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-24", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The slide uses a 'before-after' style comparison to show the potential market cap uplift for NeuroBo's assets compared to current peer valuations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/25", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "valuation_table", "function": "analyze_data", "notes": "Includes footnotes regarding anti-dilution provisions and Dong-A license agreement terms.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/26", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-26", "loopMatches": [], "arcBeatMatches": [ { "to": 26, "from": 26, "beatId": "11841772-b075-49e7-b398-2b7573fd0246", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "The document provides a financial overview", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/27", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "appendix_disclosure", "function": "establish_context", "notes": "The slide details the IP ownership status and patent expiration timelines for two specific drug candidates.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/28", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "appendix_data", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/29", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe", "docSlug": "303c45082bb692ab214f73eda43168dc", "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/30", "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe", "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-ce1e-74cc-9870-b1827d8467a5", "docSlug": "ce894072ac0bdbdb4be0c6e520599e56", "documentTitle": "Nuvalent | Investor Presentation Deck | 31 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/h_FCKAK8VQr8d4-YZJInOzeipTeLEOStFmS2x9v-sTc/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jZTg5NDA3MmFjMGJkYmRiNGJlMGM2ZTUyMDU5OWU1Ni9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ce1e-74cc-9870-b1827d8467a5/1", "deckHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5", "deckAnchorHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/c5kx5TQ8FszvN2_vEvZUKOPKubUmpyvIhqnQJpEcG28/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jZTg5NDA3MmFjMGJkYmRiNGJlMGM2ZTUyMDU5OWU1Ni9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/R6xdzlgwR7LJvgvj0PH4ASwhzeUcxvMYnSlhb7twe9Y/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jZTg5NDA3MmFjMGJkYmRiNGJlMGM2ZTUyMDU5OWU1Ni9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/BRJi5Cm5KaInOZgPiI8Vqi7bsEl_Qicql9d9uC_5Olk/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jZTg5NDA3MmFjMGJkYmRiNGJlMGM2ZTUyMDU5OWU1Ni9wMDAxLnBuZw" }, { "docId": "019de073-ce1e-74cc-9870-b1827d8467a5", "docSlug": "ce894072ac0bdbdb4be0c6e520599e56", "documentTitle": "Nuvalent | Investor Presentation Deck | 31 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de073-ce1e-74cc-9870-b1827d8467a5/2", "deckHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5", "deckAnchorHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }